Trials / Completed
CompletedNCT02970305
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 403 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin | Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth |
| DRUG | Placebo | Placebo, taken as two tablets, once daily by mouth |
Timeline
- Start date
- 2016-11-04
- Primary completion
- 2019-10-16
- Completion
- 2019-10-28
- First posted
- 2016-11-22
- Last updated
- 2020-12-22
- Results posted
- 2020-12-22
Locations
101 sites across 10 countries: United States, Bulgaria, Canada, Czechia, Hungary, Poland, Russia, Serbia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT02970305. Inclusion in this directory is not an endorsement.